Senseonics Holdings, Inc.
7.20-0.24 (-3.23%)
Oct 28, 4:00:00 PM EDT · NYSE American · SENS · USD
Key Stats
Market Cap
293.76MP/E (TTM)
-Basic EPS (TTM)
-2.00Dividend Yield
0%Recent Filings
8-K
Senseonics enacts 1-for-20 split
Senseonics Holdings executed a 1-for-20 reverse stock split, effective October 17, 2025, consolidating every 20 shares into one while slashing authorized common stock from 1,400,000,000 to 70,000,000 shares. This move, filed with Delaware on October 16, adjusts options, RSUs, and warrants proportionally, with cash for fractional shares to preserve ownership percentages. Trading resumes adjusted on NYSE American October 20 under SENS. No impact on par value.
8-K
Q3 revenue jumps 91%
8-K
Stockholders approve reverse split
Senseonics Holdings stockholders approved a flexible reverse stock split on September 29, 2025, allowing the board to implement a 1-for-10 to 1-for-20 ratio anytime before September 29, 2026, with a matching cut in authorized shares. The vote passed with 285.6 million shares in favor versus 178.2 million against and 5.0 million abstentions. This move aims to boost share price and maintain NYSE American compliance. Board discretion shapes the timing.
8-K
Senseonics reclaims Eversense commercialization
Senseonics Holdings inked a memorandum of understanding with Ascensia Diabetes Care on September 3, 2025, to reclaim commercialization of its Eversense 365 CGM system starting January 1, 2026, while Ascensia transitions operations abroad. This shift, backed by an expanded $100 million debt facility from Hercules Capital—featuring a $35 million initial draw—positions Senseonics to boost margins to 50% in 2026 through direct control. Brian Hansen joins as Chief Commercial Officer on the same date. Transition risks loom if definitive agreements falter.
8-K
Q2 revenue jumps 37%
Senseonics Holdings reported Q2 2025 revenue of $6.6 million, up 37% year-over-year, fueled by 79% growth in U.S. new patient starts for its Eversense 365 CGM system. Gross profit surged to $3.1 million from $0.3 million, thanks to higher margins and a VAT recovery, while net loss narrowed to $14.5 million. The company raised $77.8 million to support the Eversense 365 launch and pipeline development. Revenue growth accelerates in H2.
BBNX
Beta Bionics, Inc.
24.28+0.53
DXCM
DexCom, Inc.
69.23-1.40
GCTK
GlucoTrack, Inc.
7.30+0.56
ICCM
IceCure Medical Ltd.
0.76-0.03
INSP
Inspire Medical Systems, Inc.
77.17-1.03
MDT
Medtronic plc.
93.23-0.90
MODD
Modular Medical, Inc.
0.54-0.01
NMTC
NeuroOne Medical Technologies C
0.82-0.02
PODD
Insulet Corporation
324.34-1.46
TMDX
TransMedics Group, Inc.
129.71-2.74